Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Short Interest Update

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) was the target of a large decline in short interest in the month of June. As of June 30th, there was short interest totaling 102,058 shares, a decline of 47.2% from the June 15th total of 193,285 shares. Currently, 2.4% of the shares of the company are short sold. Based on an average trading volume of 212,492 shares, the days-to-cover ratio is currently 0.5 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Cyclacel Pharmaceuticals Stock Performance

BGMS traded down $0.01 during trading on Wednesday, reaching $0.90. The company’s stock had a trading volume of 25,708 shares, compared to its average volume of 1,145,566. The company’s fifty day moving average price is $0.93 and its 200-day moving average price is $1.05. Cyclacel Pharmaceuticals has a 52-week low of $0.57 and a 52-week high of $19.87. The company has a market capitalization of $4.96 million, a price-to-earnings ratio of -0.20 and a beta of -0.38.

Cyclacel Pharmaceuticals (NASDAQ:BGMS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.04) EPS for the quarter. The firm had revenue of $0.78 million during the quarter.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.